Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials
Jordi Río(Universitat Autònoma de Barcelona), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Carlos Nos(Universitat Autònoma de Barcelona), Cecilia Borrás(Hebron University), Manuel Comabella(Universitat Autònoma de Barcelona), Mar Tintoré(Vall d'Hebron Hospital Universitari), Ingrid Galán(Universitat Autònoma de Barcelona)
Cited by 126
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k